Forecast Period 
Market Size (Base Year) 
Market Size (Forecast Year)
CAGRGlobal Ramipril Market, By Product Type (Tablets, Capsules, Solutions), Indication (High Blood Pressure, Heart Failure, Diabetic Kidney Disease, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Industry Trends and Forecast to 2029.
Market Analysis and Insights
Ramipril is a drug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of drugs. It is commonly used to treat high blood pressure and heart failure. It comes as capsules, pills, and solutions for oral administration. It can be used alone or in combination with other cardiovascular medications.
Growing advancement in the formulation of the drug and adoption of ACE inhibitors for chronic disorders will help in treating high blood pressure and heart failure. Data Bridge Market Research analyses that the ramipril market was valued at USD 550 million in 2021 and likely to reach USD 729.86 million by 2029, and is estimated to grow at a CAGR of 3.6% during the forecast period of 2022 to 2029.
Report Scope and Market Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
|
Segments Covered |
Product Type (Tablets, Capsules, Solutions), Indication (High Blood Pressure, Heart Failure, Diabetic Kidney Disease, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa |
|
Market Players Covered |
Pfizer Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Lupin Pharmaceuticals, Inc. (India), Hikma Pharmaceuticals PLC (UK), Dr. Reddy’s Laboratories Ltd (India), Zydus Cadila (India), Aurobindo Pharma Limited (India), Zentiva Group, a.s. (Czechia), Novartis AG (Switzerland), WOCKHARDT (India), Perrigo Company plc (Ireland), Sanofi (France), Brown & Burk. (UK), Amneal Pharmaceuticals LLC (US), Arrow Precision Ltd. (UK), Apotex (Canada), Micro Labs Ltd. (India), Cipla Inc. (US), Pharmanova limited (Ghana), and Opsonin Pharma Limited (Bangladesh) |
|
Market Opportunities |
|
Ramipril Market Dynamics
Drivers:
Major factors that are expected to boost the growth of the ramipril market in the forecast period are as follows:
- Rise in the cardiovascular diseases
Growing cardiovascular diseases such as high blood pressure and hypertension is one of the contributing factors.
- Development in treatment
Advancement in the treatment including improvement in the formulation of the drug and growing adoption of ACE inhibitors for chronic disorders.
- Growing demand for less expensive drugs
Increase in the healthcare expenditure and rising need for better drugs is further estimated to cushion the growth of the ramipril market.
Opportunities
In addition, the rise in the research and development on the ramipril drug and advancing market regulations and financial donations from governing bodies will further provide potential opportunities for the growth of the ramipril market in the coming years.
Restraints/Challenges
On the other hand, the dangerous effects of the drugs such as rectum bleeding and stomach cramping is further projected to impede the growth of the ramipril market in the timeline period. However, the stringent regulation might further challenge the growth of the ramipril market in the near future.
This ramipril market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on ramipril market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
The ramipril market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Ramipril Market
COVID-19 has a significant impact on the ramipril market. Pharmaceutical and biotech businesses, in collaboration with governments around the world, are working to combat the COVID-19 outbreak, from vaccine development to pharmaceutical supply chain planning. Approximately 115 vaccine candidates and 155 compounds are currently being developed in the research and development pipeline. Furthermore, routinely used medications such as hydroxychloroquine have shown a huge increase in demand for COVID-19 treatment. Due to the enormous demand for these treatments, manufacturers of COVID-19 management drugs have a lot of prospects, due to COVID-19 vaccination and therapy medications are in high demand.
Recent Developments
- In 2020, the launch of ramipril for the treatment of COVID-19 (RAMIC), a placebo oral capsule for the treatment of heart failure and other cardiovascular diseases, was announced by Pfizer Inc., an American multinational pharmaceutical and biotechnology business.
- Cardiopril 5 Capsule was launched by Dr. Reddy's Laboratories, an Indian multinational pharmaceutical firm, in 2020 for the prevention of stroke, hypertension, and high blood pressure.
Global Ramipril Market
The ramipril market is segmented on the basis of product type, indication, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Tablets
- Capsules
- Solutions
On the basis of product type, the ramipril market is segmented into tablets, capsules and solutions.
Indication
- High Blood Pressure
- Heart Failure
- Diabetic Kidney Disease
- Others
On the basis of indication, the ramipril market is segmented into high blood pressure, heart failure, diabetic kidney disease and others.
End Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
On the basis of end users, the global ramipril market is segmented into hospitals, homecare, specialty clinics and others.
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
On the basis of distribution channel, the ramipril market has been bifurcated into hospital pharmacy, online pharmacy and retail pharmacy.
Ramipril Market Regional Analysis/Insights
The ramipril market is analysed and market size insights and trends are provided by country, product type, indication, end users and distribution channel as referenced above.
The countries covered in the ramipril market report are U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa.
North America dominates the ramipril market due to the several initiatives taken by the government. Furthermore, the growing funding for improving cardiovascular diseases treatment will further boost the growth of the ramipril market in the region during the forecast period.
Asia-Pacific is projected to observe significant amount of growth in the ramipril market due to the advancing healthcare amenities. Moreover, the increase in the initiatives taken by the government is further anticipated to propel the growth of the ramipril market in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Ramipril Market Share Analysis
The ramipril market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to ramipril market.
Some of the major players operating in the ramipril market are
- Pfizer Inc. (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Lupin Pharmaceuticals, Inc. (India)
- Hikma Pharmaceuticals PLC (UK)
- Dr. Reddy’s Laboratories Ltd (India)
- Zydus Cadila (India)
- Aurobindo Pharma Limited (India)
- Zentiva Group, a.s. (Czechia)
- Novartis AG (Switzerland)
- WOCKHARDT (India)
- Perrigo Company plc (Ireland)
- Sanofi (France)
- Brown & Burk. (UK)
- Amneal Pharmaceuticals LLC (US)
- Arrow Precision Ltd. (UK)
- Apotex (Canada)
- Micro Labs Ltd. (India)
- Cipla Inc. (US)
- Pharmanova limited (Ghana)
SKU-
